Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

da | postato in: Senza categoria | 0

 
A 12-week oral combination
of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high
sustained virological response rates for people with difficult-to-treat HCV
genotype 3 and other genotypes, according to phase 2 study findings presented at
the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration